Showing 3711-3720 of 5231 results for "".
- GSK Receives FDA Priority Review for Dabrafenib/Trametinib Combination in Metastatic Melanomahttps://practicaldermatology.com/news/20130916-gsk_receives_priority_review_from_fda_for_dabrafenibtrametinib_combination_in_metastatic_melanoma/2459460/The FDA has granted priority review designation to GlaxoSmithKline's supplemental New Drug Applications (sNDAs) for combined use of Tafinlar (dabrafenib) and Mekinist (trametinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 E or
- Differin Gel Found Effective in Adult Women with Acnehttps://practicaldermatology.com/news/20130807-differin_gel_found_effective_in_adult_women_with_acne/2459483/At the recent AAD Summer Meeting in New York, Galderma Laboratories presented results showing that Differin® (adapalene) Gel, 0.3% is efficacious in reducing acne lesions in adult women, and has been proven superior in reducing inflammatory lesions in women compared with vehicle gel. Investigators u
- Galen Acquires Local Dermal Analgesia Drug Synerahttps://practicaldermatology.com/news/20130716-galen_acquires_local_dermal_analgesia_drug_synera/2459495/Galen, a Northern Ireland based pharmaceutical company, has acquired Synera® (lidocaine 70mg/tetracaine 70mg) topical patch from ZARS Pharma, Inc., a wholly owned subsidiary of Nuvo Research Inc. Synera® is indicated for use on intact skin t
- European Commission Grants Conditional Approval to Erivedgehttps://practicaldermatology.com/news/20130716-european_commission_grants_conditional_approval_to_erivedge/2459497/The European Commission has granted conditional approval to Erivedge (vismodegib) for the treatment of adult patients with symptomatic metastatic basal cell carcinoma (BCC) or locally advanced BCC inappropriate for surgery or radiotherapy. The Commission granted the conditional approval based upon t
- Naftin Gel 2% Approved for Interdigital-Type Tinea Pedishttps://practicaldermatology.com/news/20130702-naftin_gel_2_approved_for_interdigital-type_tinea_pedis/2459507/The FDA approved Naftin (naftifine HCl) Gel 2% for the treatment of interdigital-type tinea pedis from Merz North America. Naftin Gel 2% improves on the current formulation of Naftin Gel 1% by delivering the efficacy of naftifine hydochloride with
- Promising Data Presented for Viviscal Oral Supplement to Promote Hair Growthhttps://practicaldermatology.com/news/20130625-promising_data_presented_for_viviscal_oral_supplement_to_promote_hair_growth/2459510/An office-dispensed oral food supplement appears to promote existing hair growth for women suffering from temporary thinning hair, according to data presented at the World Hair Congress in Edinburgh, Scotland this spring. Subjects treated with Viviscal Hair Nourishment System
- Phase III Data Show Galderma's Topical Redness Reducer is Effective, Safehttps://practicaldermatology.com/news/20130625-phase_iii_data_show_galdermas_topical_redness_reducer_is_effective_safe/2459511/Topical brimonidine tartrate gel 0.5% is safe and effective for the management of erythema of rosacea, with benefit evidence as early as 30 minutes after application, new data show. (JDD, 12(6):650-656) Data from two identically designed randomized, double-blind, vehicle controlled phase III trials
- Geneticists Research Cleft Palate and Skin Deformitieshttps://practicaldermatology.com/news/20130614-geneticists_research_cleft_palate_and_skin_deformities/2459514/Scientists at Cold Spring Harbor Laboratory (CSHL) solved the mystery of why some infants are born with cleft palate and major deformities of the skin and limbs, while other infants with the same genetic mutation bear little or no sign of the illness, called Ectodactyly, Ectodermal dysplasia, Clefti
- National Psoriasis Foundation Awards Research Grantshttps://practicaldermatology.com/news/20130610-national_psoriasis_foundation_awards_research_grants/2459519/Six scientists received National Psoriasis Foundation (NPF) research grants totaling $450,000 for projects that aim to discover new treatments and a cure for psoriasis and psoriatic arthritis. Theoharis Theoharides, MD, PhD received a
- Renaissance and GlaxoSmithKline Transfer Nine Productshttps://practicaldermatology.com/news/20130605-renaissance_and_glaxosmithkline_transfer_nine_products/2459522/Renaissance Acquisition Holdings, LLC and GlaxoSmithKline entered into an agreement giving Renaissance the rights in the USA to manufacture, market, and sell six dermatology and three anti-viral products from GSK. The products from GSK and Stiefel, which will be marketed through Renaissance's bran